Advertisement

Keywords

Renal Insufficiency Plasma Protein Binding Common Side Effect Peak Plasma Level Main Reference 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aurell M, Delin K, Herlitz H, Ljungman S, Witte PU, Irmisch R: Pharmacokinetics and pharmacodynamics of ramipril in renal failure. Am J Cardiol 59:65D, 1987PubMedCrossRefGoogle Scholar
  2. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, Kuan TS, Mora J, Walter U, Eckert HG, Hajdu P, Metzger H: Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol 59:70D, 1987PubMedCrossRefGoogle Scholar
  3. Doering W, Maass L, Irmisch R, König E: Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. Am J Cardiol 59:60D, 1987PubMedCrossRefGoogle Scholar
  4. Ramipril (HOE 498), (ACE inhibitor) Investigators Brochure, March 1988. Clinical Research Dept. Hoechst Aktiengesellschaft, Frankfurt am Main, GermanyGoogle Scholar

Main references

  1. Bogues K, Dixon GT, Fowler P, Jenner WN, Maconochie JG, Martin LE, Willoughby BA: Pharmacokinetics and bioavailability of ranitidine in humans. Br J Pharmacol 73:275P, 1981Google Scholar
  2. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS: Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24:267, 1982PubMedCrossRefGoogle Scholar
  3. Chau NP, Zech PY, Pozet N, Hadj-aissa A: Ranitidine kinetics in normal subjects. Clin Pharmacol Ther 31:770, 1982PubMedCrossRefGoogle Scholar
  4. Garg DC, Weidler DJ, Baltodano N, Eshelman FN: Pharmacokinetics of ranitidine, a new histamine H2-receptor blocker. Clin Pharmacol Ther 29:247, 1981Google Scholar
  5. Garg DC, Baltodano N. Perez GO, Oster JR, Jallad NS, Weidler DJ: Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients. Pharmacology 31:189, 1985PubMedCrossRefGoogle Scholar
  6. Ireland A, Colin-Jones DG, Gear P, Golding PL et al.: Ranitidine 150 mg twice daily vs 300 mg nightly treatment of duodenal ulcers. Lancet II:274, 1984CrossRefGoogle Scholar
  7. Konturek SJ, Obtulowics W, Kwiecien N, Kopp B, Oleksy J: Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients. Scand J Gastroenterol 16 (Suppl 69):91, 1981Google Scholar
  8. Langman MJS, Henry DA, Bell GD, Burnham WR, Ogilvy A: Cimetidine and ranitidine in duodenal ulcer. Br Med J 2:473, 1980CrossRefGoogle Scholar
  9. Martin LE, Oxford J, Tanner RJN: Use of high-performance liquid chromatography-mass spectrometry for the study of the metabolism of ranitidine in man. J Chromatogr 251:215, 1982PubMedCrossRefGoogle Scholar
  10. McFadyen ML, Folb Pl. Miller R, Keeton GR, Marks IN: Pharmacokinetics of ranitidine in patients with chronic renal failure. Eur J Clin Pharmacol 25:347, 1983PubMedCrossRefGoogle Scholar
  11. McGonigle RJS, Williams LC, Amphlett GE, England RJ, Parsons V: The pharmacokinetics of ranitidine in renal disease. In: Misiewicz JJ, Wormsley KG (eds): The clinical use of ranitidine. Oxford: Medicine Publ. Foundation, 1982 p41Google Scholar
  12. Meffin PJ, Grgurinovich N, Brooks PM, Miners JO, Cochran M, Stranks G: Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol 16:731, 1983PubMedCrossRefGoogle Scholar
  13. Roberts AP, Harrison C, Dixon GT, Curtis JR: Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients. Postgrad Med J 59:25, 1983PubMedCrossRefGoogle Scholar
  14. Sica DA, Comstock T, Harford A, Eshelman F: Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 32:587, 1987PubMedCrossRefGoogle Scholar
  15. Woodings EP, Dixon GT, Harrison C, Carey P, Richards DA: Ranitidine — a new H2-receptor antagonist — Gut 21:187, 1980PubMedCrossRefGoogle Scholar
  16. Young CJ, Daneshmend TK, Roberts CJC: Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine. Gut 23:819, 1982PubMedCrossRefGoogle Scholar
  17. Zeldis JB, Friedman LS, Isselbacher KJ: Ranitidine: A new H2-receptor antagonist. N Engl J Med 309:1368, 1983PubMedCrossRefGoogle Scholar

Main references

  1. Niebch G, Obermeier K, Vergin H, Thiemer K: Untersuchungen zur Pharmakokinetik und Biotransformation von Reproterol bei Tier und Mensch. Arzneimittelforschung (Drug Res) 27:37, 1977Google Scholar
  2. Niebch G, Klingler KH, Eikelmann G, Kucharczyk N: Untersuchungen zur Biotransformation von Reproterol. Strukturaufklärung des Hauptmetaboliten. Arzneimittelforschung (Drug Res) 28(I):765, 1978Google Scholar

Main references

  1. Maass AR, Jenkins B, Shen Y, Tannenbaum P: Studies on absorption, excretion and metabolism of 3H-reserpine in man. Clin Pharmacol Ther 10:366, 1969PubMedGoogle Scholar
  2. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:498, reserpineGoogle Scholar
  3. Planz G, Rahn KH: Pharmakokinetik antiypertensiv wirksamer Pharmaka bei Niereninsuffizienz. Nieren- und Hochdruckkrankh 8:51, 1979Google Scholar
  4. Stitzel RE: The biological fate of reserpine. Pharmacol Rev 28:179, 1977Google Scholar
  5. Zsoter TT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14:325, 1973PubMedGoogle Scholar

Main references

  1. De Bevere VORC, De Paepe M, De Leenheer AP, Nelis HJCF, Lambert WEES, Claeys AE, Ringoir S: Plasma vitamin A in haemodialysis patients. Clin Chim Acta 114:249, 1981PubMedCrossRefGoogle Scholar
  2. Kopple JD, Swendseid ME: Vitamin nutrition in patients undergoing maintenance hemodialysis. Kidney Int 7 (Suppl 2):S79, 1975Google Scholar
  3. Popper H, Steigmann F, Dyniewicz HA: Plasma vitamin A level in renal disease. Am J Clin Pathol 15:272, 1945Google Scholar
  4. Shmunes E: Hypervitaminosis A in a patient with alopecia receiving renal dialysis. Arch Dermatol 115:882, 1979PubMedCrossRefGoogle Scholar
  5. Smith FR, Goodman DWS: Vitamin A transport in human vitamin A toxicity. N Engl J Med 294:805, 1976PubMedCrossRefGoogle Scholar
  6. Vahlquist A, Berne B, Danielson BG, Grefberg N, Berne C: Vitamin A losses during continuous ambulatory peritoneal dialysis. Nephron 41:179, 1985PubMedCrossRefGoogle Scholar
  7. Werb R, Clark WF, Lindsay RM, Jones EOP, Linton AL: Serum vitamin A levels and associated abnormalities patients on regular dialysis treatment. Clin Nephrol 12:63, 1979PubMedGoogle Scholar
  8. Werb R: Vitamin A toxicity in hemodialysis patients. Int J Artif Organs 2:178, 1979PubMedGoogle Scholar
  9. Yatzidis H, Digenis P, Fountas P: Hypervitaminosis A accompanying advanced chronic renal failure. Br Med J 3:352, 1975PubMedCrossRefGoogle Scholar

Main references

  1. Jusko WJ, Levy G, Yaffe SJ et al.: Effect of probenecid on renal clearance of riboflavin in man. J Pharm Sci 59:473, 1970PubMedCrossRefGoogle Scholar
  2. Jusko WJ, Levy G: In: Rivlin RJ (ed): Riboflavin. New York: Plenum Press, 1975 p 99CrossRefGoogle Scholar
  3. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:1272, riboflavinGoogle Scholar
  4. Stein G, Sperschneider H, Koppe S: Vitamin levels in chronic renal failure and need for supplementation. Blood Purif 3:52, s1985PubMedCrossRefGoogle Scholar

Main references

  1. Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3:108, 1978PubMedCrossRefGoogle Scholar
  2. Amedia C, Oettinger CW: Unusual presentation of tuberculosis in chronic hemodialysis patients. Clin Nephrol 8:363, 1977PubMedGoogle Scholar
  3. Andrews OT, Schoenfeld PY, Hopeneil PC, Humphreys MW: Tuberculosis in patients with end-stage renal disease. Am J Med 68:59, 1980CrossRefGoogle Scholar
  4. Baciewicz AM, Self TH, Beckemeyer WB: Update on rifampin drug interactions. Arch Intern Med 147:565, 1987PubMedCrossRefGoogle Scholar
  5. Campese VM, Marzullo F, Schena FP, Coratelli P: Acute renal failure during intermittent rifampicin therapy. Nephron 10:256, 1973PubMedCrossRefGoogle Scholar
  6. Cochran M, Moorhead PJ, Platts M: Permanent renal damage with rifampicin. Lancet I:1428, 1975CrossRefGoogle Scholar
  7. Cordonnier D, Muller JM: Acute renal failure after rifampicin. Lancet II:1364, 1972CrossRefGoogle Scholar
  8. Curci G, Bergamini F, Deli V et al.: Half life of rifampicin after repeated administration of different doses in humans. Chemotherapy 17:373, 1972PubMedCrossRefGoogle Scholar
  9. Gabow PA, Lacher JW, Neff TA: Tubulointerstitial and glomerular nephritis associated with rifampicin: Report of a case. JAMA 235:2517, 1976PubMedCrossRefGoogle Scholar
  10. Hendrickse W, McKierman J, Peckup M, Lowe J: Rifampicin induced nonresponsiveness to corticosteroid treatment in nephrotic syndrome. Br Med J 1:306, 1979PubMedCrossRefGoogle Scholar
  11. Kenny MT, Strates B: Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 12:159, 1981PubMedCrossRefGoogle Scholar
  12. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:570, rifampicin.Google Scholar
  13. McGeachie J, Girdwood RWA, Burton JA et al.: Impaired renal function and serum levels of rifampicin. Scoff Med J 15:257, 1970Google Scholar
  14. Nitti V, Delli V, Ninni A et al.: Rifampicin blood serum levels and half life during prolonged administration in tuberculous patients. Chemotherapy 17:121, 1972PubMedCrossRefGoogle Scholar
  15. Power DA, Russel G, Smith FW, Simpson JG, MacLeod AM, Friend JAR, Catto GRD: Acute renal failure due to continuous rifampicin.Clin Nephrol 20:155, 1983PubMedGoogle Scholar
  16. Pradhan RP, Katz LA, Nidus BD et al.: Tuberculosis in dialyzed patients. JAMA 229:798, 1974PubMedCrossRefGoogle Scholar
  17. Ramgopal V, Leonard C, Bhathena D: Acute renal failure associated with rifampicin. Lancet I:1195, 1973CrossRefGoogle Scholar
  18. Reed MD, Blumer JL: Clinical pharmacology of antitubercular drugs. Pediatr Clin North Am 30:177, 1983PubMedGoogle Scholar
  19. Seufert CD: Acute renal failure after rifampicin therapy. Scand J Respir Dis (Suppl) 84:174, 1973Google Scholar
  20. Smith FW, Catto GRD, Macleod M: Treatment of pulmonary tuberculosis in a patient on maintenance haemodialysis. Postgrad Med J 50:478, 1974PubMedCrossRefGoogle Scholar
  21. Urbanczik R: Tuberkulosetherapie bei Patienten mit Niereninsuffizienz, Dialyse und nach Nierentransplantation. Prax Klin Pneumol 37:436, 1983PubMedGoogle Scholar

Main references

  1. Gandar R, de Zoeten LW, van der Schoot JB: Serum level of ritodrine in man. Eur J Clin Pharmacol 17:117, 1980PubMedCrossRefGoogle Scholar
  2. Siimes ASI, Creasy RK: Maternal and fetal metabolic responses to ritodrine in the sheep. Acta Obstet Gynecol Scand 59:181, 1980PubMedCrossRefGoogle Scholar

Main references

  1. Martindale. The extra pharmacopoeia. 29th ed. London: The Pharmaceutical Press, 1989:293, rolitetracyclineGoogle Scholar
  2. Otten H, Plempel M, Siegenthaler W (eds) Antibiotika-Fibel: N-Pyrrolidinomethyl-tetracyclin, 4th ed. Stuttgart: Georg Thieme Verlag, 1975 p 340Google Scholar

Main references

  1. Edelson J, Davison C, Benziger DP: Quinolone and ‘azaquinolone’ antibacterial agents. Drug Metab Rev 6:105, 1977CrossRefGoogle Scholar
  2. Kullberg MP, Koss R, O’Neil S, Edelson J: High-performance liquid chromatographic analysis of rosoxacin and its N-oxide metabolite in plasma and urine. J Chromatogr 173:155, 1979PubMedCrossRefGoogle Scholar
  3. Park GB, Saneski J, Weng T, Edelson J: Pharmacokinetics of rosoxacin in human volunteers. J Pharm Sci 71:461, 1982PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • Günter Seyffart
    • 1
  1. 1.Dialysis CenterBad HomburgGermany

Personalised recommendations